Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy
Background: Current treatments of unresectable hepatocellular carcinoma (HCC) are trans-arterial chemo-embolization (TACE), stereotactic body radiotherapy (SBRT), and targeted therapy. However, these treatments are limited in efficacy and safety for patients with large tumor sizes. Here, we report a...
Main Authors: | Chi-Leung Chiang, Albert C. Y. Chan, Keith W. H. Chiu, Feng-Ming (Spring) Kong |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.01157/full |
Similar Items
-
Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients
by: Ming-Wei Ma, et al.
Published: (2022-10-01) -
Effectiveness of individual audio-visual coaching, respiratory modulated stereotactic body radiotherapy for localized hepatocellular carcinoma: Analysis of 29 cases from a single academic radiotherapy center
by: Liang-Cheng Chen, et al.
Published: (2021-01-01) -
Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors
by: Atalar Banu, et al.
Published: (2020-06-01) -
Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial
by: Liang-Cheng Chen, et al.
Published: (2019-03-01) -
A Phase II Trial of SABR (Stereotactic Ablative Body Radiotherapy) for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life and Disease Control Outcomes with 5-Year Minimum Followup
by: Constantine Anastasios Mantz
Published: (2014-11-01)